JPH08291056A - Plaster - Google Patents

Abstract

PURPOSE: To obtain a plaster enabling the effective absorption of a drug per cutaneously or through mucosa by placing a specific adhesive layer on one face of a supporting body and capable of effectively red-easing the drug by absorbing water, sweat, etc., evaporating from the skin or the mucosa. CONSTITUTION: (B) An adhesive layer consisting of (i) a crosslinked polyacrylic acid salt impregnated with an electrolyte (e.g. NaCl) or a strong acid (e.g. hydrochloric acid), (ii) a drug (e.g. indomethacin) and (iii) an adhesive base material is formed on one face of (A) a supporting body. The component (i) swells by absorbing water but does not swell by incorporating the component (ii). Further, the component (iii) is preferably a (co)polymer composed mainly of a (meth)acrylic acid alkyl ester such as hexyl (meth)acrylate, etc.

Description

Detailed Description of the Invention

[0001]

FIELD OF THE INVENTION The present invention relates to a patch.

[0002]

2. Description of the Related Art Conventionally, various studies have been carried out in order to enhance the effect of promoting percutaneous absorption of a drug in a patch, for example, JP-A-4-13617 contains a water-absorbing filler. Disclosed patches are disclosed. But,
When a cross-linked polyacrylic acid salt is used as a water-absorbing filler, the effect of promoting percutaneous absorption is improved, but after application, the cross-linked polyacrylic acid salt swells 100 times or more due to perspiration from the skin and moisture that evaporates. Therefore, there are problems that the adhesive layer is cracked or peeled off from the skin so that it cannot be sufficiently contacted with the skin and the drug absorbability is lowered.

[0003]

SUMMARY OF THE INVENTION The present invention has been made to solve the above-mentioned drawbacks, and its object is to efficiently release a drug contained in an adhesive layer,
It is to provide a patch that can be effectively absorbed into the body through the skin or mucous membranes.

[0004]

[Means for Solving the Problems]

In the patch of the present invention, a pressure-sensitive adhesive layer comprising a crosslinked polyacrylic acid salt impregnated with an electrolyte or a strong acid, a drug and a pressure-sensitive adhesive base is formed on one surface of a support.

As the support used in the present invention, those generally used as a support for patches can be used, such as cellulose acetate, ethyl cellulose,
Resin films such as polyethylene terephthalate, plasticized vinyl acetate-vinyl chloride copolymer, polyamide, ethylene-vinyl acetate copolymer, plasticized polyvinyl chloride, polyurethane, polyvinylidene chloride: aluminum sheets and the like. It may be used as a layered sheet or as a laminate of two or more kinds. Further, other than the aluminum sheet, it may be used as a woven fabric or a non-woven fabric.

Examples of the adhesive base used in the present invention include acrylic adhesives, rubber adhesives, silicone adhesives and the like. Considering adhesive physical properties and cost, acrylic adhesives and rubbers are used. A system adhesive is preferable.

Examples of the acrylic pressure-sensitive adhesive include
Mainly composed of (meth) acrylic acid alkyl ester (co)
A polymer is preferably used, but it may be a copolymer with a functional monomer, a polyfunctional monomer, a vinyl compound or the like, which is copolymerizable with the (meth) acrylic acid alkyl ester.

As the above-mentioned (meth) acrylic acid alkyl ester, when the carbon number of the alkyl group is reduced, the cohesive force is improved, but the adhesive force is decreased, and when it is increased, the adhesive force is improved but the cohesive force is decreased. Those obtained from the aliphatic alcohol of the number 2 to 18 and (meth) acrylic acid are preferable, and for example, hexyl acrylate, 2-ethylhexyl (meth) acrylate, octyl (meth) acrylate, isooctyl (meth) acrylate. , (Meth) decyl acrylate, (meth) isodecyl acrylate, (meth)
Dodecyl acrylate, lauryl (meth) acrylate,
Examples thereof include stearyl (meth) acrylate, which may be used alone or in combination of two or more kinds.

Examples of the functional monomer include a monomer having a hydroxyl group, a monomer having a carboxyl group, a monomer having an amide group, a monomer having an amino group, and the like.

As the above-mentioned monomer having a hydroxyl group, for example, hydroxyalkyl (meth) acrylate such as 2-hydroxyethyl (meth) acrylate and hydroxypropyl (meth) acrylate are preferably used.

Examples of the monomer having a carboxyl group include α, β such as (meth) acrylic acid.
-Unsaturated carboxylic acid; maleic acid monoalkyl ester such as butyl maleate; (anhydrous) maleic acid, fumaric acid, crotonic acid, etc. are preferably used.

Examples of the monomer having an amide group include alkyl (meth) acrylamides such as acrylamide, dimethylacrylamide and diethylacrylamide; alkyl ether methylol (meth) acrylamides such as butoxymethyl acrylamide and ethoxymethyl acrylamide; diacetone acrylamide. It is preferably used.

As the monomer having an amino group, for example, dimethylaminoethyl acrylate is preferably used.

Examples of the polyfunctional monomer include
1,6-hexane glycol dimethacrylate, tetraethylene glycol diacrylate, trimethylolpropane triacrylate, divinylbenzene, divinyltoluene, diallyl phthalate and the like can be mentioned.

As the vinyl compound, vinyl acetate,
Examples thereof include styrene, α-methylstyrene, N-vinyl-2-pyrrolidone, vinyl chloride, acrylonitrile, ethylene, propylene and butadiene, which may be copolymerized.

The content of the (meth) acrylic acid alkyl ester in the constituents of all the copolymers is preferably 50% by weight or more.

The (co) polymer mainly composed of the (meth) acrylic acid alkyl ester is usually prepared by blending the above-mentioned monomers in the presence of a polymerization initiator and carrying out solution polymerization. When performing solution polymerization, ethyl acetate or other polymerization solvent is added to a predetermined amount of various monomers, in an reactor equipped with a stirrer and a cooling reflux device, azobis,
7 in a nitrogen atmosphere in the presence of a polymerization initiator such as a peroxide type.
The reaction may be performed at 0 to 90 ° C for 8 to 40 hours. Further, the monomer may be charged all at once or dividedly.

As the azobis type polymerization initiator, 2,
2-azobis-iso-butyronitrile, 1,1'-azobis (cyclohexane-1-carbonitrile), 2,2'-
Examples thereof include azobis (2,4-dimethylvalerinitrile), and examples of the peroxide-based polymerization initiator include lauroyl peroxide, benzoyl peroxide, di (tert-butyl) peroxide, and the like.

Examples of the rubber-based pressure-sensitive adhesive include natural rubber, synthetic isoprene rubber, polyisobutylene, polyisoprene, polybutadiene, styrene-butadiene copolymer,
Examples of the main component include a styrene-isoprene copolymer and a styrene-isoprene-styrene block copolymer.

Examples of the above silicone-based pressure-sensitive adhesives include those containing silicon gum such as polyorganosiloxane as a main component.

If desired, tackifiers, softeners, plasticizers, fillers, antioxidants, etc. may be added to the above-mentioned pressure-sensitive adhesive base. As the tackifier, for example, rosin,
Rosin-based resins such as hydrogenated rosin, disproportionated rosin and rosin ester; terpene-based resins such as α-pinene and β-pinene;
Terpene phenol resin; Petroleum resin; Alkyl-phenol resin; Xylene resin; Coumaron resin; Coumaron-
Examples thereof include indene resin.

Examples of the softening agent include liquid polybutene, mineral oil, lanolin, liquid isobutylene, liquid polyacrylate and the like.

The plasticizer is preferably one that adjusts the viscosity of the pressure-sensitive adhesive layer and promotes the transdermal or transmucosal absorbability of the drug described below, and is safe for the human body. . Examples of such plasticizers include cetyl octanoate, hexyl laurate, isopropyl myristate, octyldodecyl myristate, isopropyl palmitate, octyl palmitate, butyl stearate, octyl stearate, octyl hydroxystearate, isononane. Monohydric alcohol fatty acid esters such as isotridecyl acid, ethyl oleate, decyl oleate, mink oil fatty acid ester, myristyl lactate; dibasic acids such as diisopropyl adipate, dioctyl adipate, diethyl sebacate, dioctyl sebacate, dioctyl succinate, etc. Ester; Propylene glycol dicaprate, glyceryl trioctanoate, glyceryl tri (octanoic acid / decanoate), glyceryl tripalmitate, sorbitan oleate, Polyhydric alcohol fatty acid esters such as sexual fatty oils; olive oil, safflower oil,
Animal and vegetable oils such as coconut oil fatty acid triglyceride and cottonseed oil;
Hydrocarbons such as scrawan, α-olefin oligomer, liquid paraffin and wax; alcohols such as cetanol, behenyl alcohol, 2-hexyldecanol, 2-octyldecanol and oleyl alcohol; ethers such as polyoxyethylene lauryl ether and polyoxyethylene oleyl ether Amide compounds such as oleic acid amide and lauric acid monoethanolamide; silicones such as dimethylpolysiloxane and methylphenylpolysiloxane.

Since the cohesive force of the pressure-sensitive adhesive decreases as the amount of the plasticizer compounded increases, it is preferably 300 parts by weight or less, more preferably 3 to 200 parts by weight, relative to 100 parts by weight of the pressure-sensitive adhesive base. Is.

The crosslinked polyacrylic acid salt used in the present invention is one that absorbs water and swells, but does not swell by the adhesive base and the drug described below. Examples thereof include crosslinked polyacrylic acid salt and starch. -Crosslinked products of polyacrylic acid salt graft copolymers and the like can be mentioned. The crosslinked polyacrylic acid salt is impregnated with an electrolyte or a strong acid for the purpose of weakening ionic crosslinking. Examples of the electrolyte include inorganic salts such as Nacl, Kcl, and Cacl _{2, and} examples of the strong acid include hydrochloric acid, nitric acid, and the like.

The method of impregnating the above-mentioned electrolyte is not particularly limited, but generally, a 0.1 to 10% by weight aqueous solution of the electrolyte is prepared, and a cross-linked polyacrylic acid salt is added in an amount equal to this aqueous solution to form a cross-linked polyacrylic acid. After absorption in an acrylate salt, a freeze-drying method can give a crosslinked polyacrylate salt impregnated with an electrolyte or a strong acid.

If the amount of the above-mentioned electrolyte added is small, the swelling-suppressing effect is difficult to be exhibited, and if the amount is too large, the electrolyte cannot be completely impregnated and crystals of the electrolyte are liable to occur. 0.1 to 10 parts by weight is preferable, and 0.5 to 5 parts by weight is more preferable.

The method of impregnating the above strong acid is not particularly limited, but generally, an aqueous solution of a strong acid is prepared, and an equal amount of the crosslinked polyacrylic acid salt is added to the solution so that the crosslinked polyacrylic acid salt is absorbed. Then, a freeze-drying method can be used to obtain a crosslinked polyacrylate impregnated with a strong acid.

If the amount of the above strong acid added is small, the swelling-inhibiting effect is difficult to develop, and if it is too large, the crosslinked polyacrylic acid salt is difficult to swell, and the transdermal absorption-promoting effect of the drug is difficult to be developed. The number of moles of the carboxylic acid group contained in acrylic acid is preferably 5 to 80%, more preferably 10 to 50%.

If the water absorption rate of pure water of the crosslinked polyacrylic acid salt impregnated with the above-mentioned electrolyte or strong acid becomes small, the effect of promoting percutaneous absorption of the drug becomes difficult to be expressed. Since cracks and the like occur, it is preferably 2 to 50 times, more preferably 5 to 10 times.

In the pressure-sensitive adhesive layer, when the amount of the cross-linked polyacrylate impregnated with the electrolyte or strong acid is small, the effect of promoting percutaneous absorption of the drug is difficult to be expressed, and when the amount is large, the adhesiveness of the patch is lowered. 0.5 to 20 in the adhesive base
Weight percent is preferred.

The above-mentioned drugs include the following. Indomethacin, salicylic acid, aspirin, acetaminophenone, diclofenac sodium, ibuprofen, sulindac, naproxen, ketoprofen, flufenamic acid, ibufenac, fenbufen, alclofenac, phenylbutazone, mefenamic acid, bendazac, piroxicam, flurbiprofen, pentazocine , Buprenorphine hydrochloride, butorphanol tartrate and other antipyretic and anti-inflammatory analgesics; hydrocortisone,
Prednisolone, fluocinolone acetonide, fludoxycortide, methylprednisolone, hydrocortisone acetate, triamcinolone acetonide, dexamethasone,
Steroidal anti-inflammatory agents such as hetamethasone acetate, diflucortron valerate, propionclohetazole, and fluocinonide.

Diltiazem, verapamil, pentaerythritol tetranitrate, dipyridamole, isosorbide dinitrate,
Vasodilators such as nifedipine and nitroglycerin; propranolol, atenolol, pindolol, quinidine sulfate, azimarin, alprenolol hydrochloride, metoprolol tartrate, nadolol, timolol maleate, disopyramide and other hypertensive / arrhythmic agents; clonidine hydrochloride, captoril, hydrochloric acid Antihypertensive agents such as prazosin, benbutolol sulfate, guanabenz acetate, guanfacine hydrochloride, punazosin hydrochloride, ellanapril maleate, arotinolol hydrochloride, and bunitrolol hydrochloride.

Procaterol hydrochloride, terbutaline sulfate,
Fenoterol hydrobromide, tulobuterol hydrochloride, ambroxol hydrochloride, purbuterol hydrochloride, mabuterol hydrochloride, clenbuterol hydrochloride, trimethoquinol hydrochloride,
Antitussive expectorants such as formoterol fumarate; antitumor agents such as 5-fluorouracil, 1- (2-tetrahydrofuryl) -5-fluorouracil and mitomycin C.

Benzocaine, procaine, lidocaine,
Local anesthetics such as tetracaine; steroid hormones such as estrogen, estradiol, testosterone, progesterone and prostaglandins; peptide hormones such as insulin.

Anti-asthma / nasal allergic agents such as ketotifen fumarate, azelastine hydrochloride, sodium cromoglycate; antihistamines such as cycloheptazine hydrochloride, diphenhydramine hydrochloride, fenbenzamine, metacidine; anticoagulants such as heparin; scopolamine, clopolmine Antispasmodic such as fluperol.

Cerebral circulatory metabolism-improving agents such as pinpocetine, flunarizine hydrochloride, nicardipine hydrochloride, brovincamin fumarate, dihydroergotoxine mesylate, ifenprodil tartrate, isoxuprine hydrochloride; maprotiline hydrochloride,
Antidepressant / Anxiolytic drugs such as etizolam, diazepam, bromazepam, amitriptyline hydrochloride, mianserin hydrochloride; α
-Vitamin D such as calcidol, ergocasiferol
Agents: oral hypoglycemic agents such as glibenclamide and gliclazide.

Antiulcer agents such as grepopride malate, famotidine, glycopyrronium bromide and the like; sleeping pills such as phenobarbital and amobarbital; tetracycline,
Antibiotics such as chloramphenicol.

The compounding amount of the above-mentioned drug varies depending on the kind of the drug and the purpose of use of the preparation, but if the amount is small, a high drug releasing property cannot be obtained, and if the amount is large, the cohesive force and the adhesive force of the adhesive layer are lowered. Usually, 0.1 to 30% by weight in the pressure-sensitive adhesive layer is preferable.

The patch of the present invention is produced according to a usual method for producing an adhesive tape. For example, solvent coating method,
Conventionally known methods for producing an adhesive tape such as a hot melt coating method, an electron beam curing method and an emulsion coating method can be used, but a solvent coating method is particularly preferably used.

In the solvent coating method, the adhesive base is diluted with an appropriate solvent, and the above-mentioned drug, cross-linked polyacrylic acid salt and, if necessary, other additives are added to obtain the solution. The adhesive solution is applied to the surface of the support and dried to remove the solvent, whereby a pressure-sensitive adhesive layer can be formed on the support to prepare a patch. Further, this solution may be coated on a release paper and dried, and then transferred to a support to form an adhesive layer. Further, this release paper may be stuck until the time of use for the purpose of protecting the pressure-sensitive adhesive layer.

The thickness of the above-mentioned pressure-sensitive adhesive layer varies depending on the purpose of use, but when it becomes thin, the amount of drug per unit area of the patch becomes insufficient, and when it becomes thick, the drug contained in the pressure-sensitive adhesive layer near the support diffuses. This makes it difficult to reach the skin surface, and the drug in the adhesive layer will not be effectively used.
30 to 2,000 μm is preferable.

[0044]

Next, embodiments of the present invention will be described. (Example 1) A copolymer obtained by copolymerizing 45 parts by weight of 2-ethylhexyl acrylate and 55 parts by weight of 2-ethylhexyl methacrylate was dissolved in ethyl acetate to give an adhesive having a solid content concentration of 34% by weight. A base solution was obtained. Further, while stirring 100 parts by weight of the starch-acrylic acid salt graft copolymer cross-linked product (“Sun Fresh” manufactured by Sanyo Kasei Co., Ltd.) with a dissolver, 100 parts by weight of a 1 wt% NaCl aqueous solution was added and freeze-dried to obtain NaCl. An impregnated crosslinked polyacrylate was obtained.

To the above adhesive base solution, 10% by weight ethyl isosorbide nitrate acetate solution and NaCl-impregnated crosslinked polyacrylic acid salt were added so as to have the composition shown in Table 1, and uniformly mixed by stirring with a dissolver. , Solid content concentration 30
A wt% ethyl acetate dispersion solution was prepared. This dispersion solution was applied onto polyethylene terephthalate release paper so that the thickness after drying would be 100 mμ, and dried at 60 ° C. for 30 minutes to form an adhesive layer. Next, this adhesive layer was transferred and laminated on the polyethylene terephthalate side of a polyethylene terephthalate / ethylene / vinyl acetate copolymer laminated film (support) to prepare a patch.

(Comparative Examples 1 and 2) Patches were prepared in the same manner as in Example 1 except that the pressure-sensitive adhesives were formed by using the predetermined amounts of the components shown in Table 1.

Example 2 A copolymer obtained by copolymerizing 85 parts by weight of 2-ethylhexyl acrylate and 15 parts by weight of N-vinylpyrrolidone was dissolved in ethyl acetate.
An adhesive base solution having a solid content concentration of 33.2% by weight was obtained. While stirring 100 parts by weight of crosslinked polyacrylate (“Sun Fresh” manufactured by Sanyo Kasei Co., Ltd.) with a dissolver,
The mixture was added to 100 parts by weight of a 5 wt% CaCl ₂ aqueous solution and freeze-dried to obtain a CaCl ₂ -impregnated crosslinked polyacrylate.

Indomethacin, C was added to the above adhesive base solution.
A cross-linked polyacrylic acid salt impregnated with aCl ₂ was added so as to have the composition shown in Table 1 and uniformly mixed by stirring with a dissolver to prepare an ethyl acetate dispersion solution having a solid content concentration of 30% by weight. Using this dispersion solution, a patch was prepared in the same manner as in Example 1.

(Comparative Examples 3 and 4) Patches were prepared in the same manner as in Example 2 except that the pressure-sensitive adhesives were formed using the prescribed amounts of the components shown in Table 1.

Example 3 Styrene-isoprene-styrene copolymer ("Califlex TR1" manufactured by Shell Chemical Co., Ltd.
107P "), 100 parts by weight, alicyclic saturated hydrocarbon resin (Arakawa Chemical Co., Ltd." Alcon P85 ") 95 parts by weight, and isopropyl myristate 30 parts by weight under nitrogen substitution.
The mixture was uniformly stirred and mixed at 0 ° C. to obtain an adhesive base solution having a solid content concentration of 84% by weight. Further, 100 parts by weight of crosslinked polyacrylate (“Sun Fresh” manufactured by Sanyo Kasei Co., Ltd.) was added to 100 parts by weight of a 2% by weight KCl aqueous solution while stirring with a dissolver, and lyophilized to give KCl-impregnated crosslinked polyacrylic acid. The acid salt was obtained.

The above adhesive base solution was added with nitrogen substitution at 110 ° C.
Then, indomethacin and KCl-impregnated crosslinked polyacrylic acid salt were added so as to have the composition shown in Table 1, and were uniformly mixed with stirring by a dissolver to prepare an adhesive solution. Using this adhesive solution, a patch was prepared in the same manner as in Example 1.

(Comparative Examples 5 and 6) Patches were prepared in the same manner as in Example 3 except that the pressure-sensitive adhesives were formed using the prescribed amounts of the components shown in Table 1.

Example 4 A copolymer obtained by copolymerizing 45 parts by weight of 2-ethylhexyl acrylate and 55 parts by weight of 2-ethylhexyl methacrylate was dissolved in ethyl acetate to obtain a solid concentration of 34 parts by weight. % Adhesive solution was obtained. While stirring 100 parts by weight of starch / acrylic acid salt graft copolymer cross-linked product (“Sun Fresh” manufactured by Sanyo Kasei Co., Ltd.) with a dissolver, 100 parts by weight of 1% by weight HCl aqueous solution was added, and freeze-dried to form HCl. An impregnated crosslinked polyacrylate was obtained.

To the above-mentioned adhesive base solution, 10 wt% isosorbide dinitrate ethyl acetate solution and cross-linked polyacrylic acid salt impregnated with HCl were added so as to have the composition shown in Table 2, and uniformly mixed by stirring with a dissolver. , Solid content concentration 30
A wt% ethyl acetate dispersion solution was prepared. Using this dispersion solution, a patch was prepared in the same manner as in Example 1.

(Comparative Examples 7 and 8) Patches were prepared in the same manner as in Example 4 except that the pressure-sensitive adhesives were formed using the prescribed amounts of the components shown in Table 2.

Example 5 A copolymer obtained by copolymerizing 85 parts by weight of 2-ethylhexyl acrylate and 15 parts by weight of N-vinylpyrrolidone was dissolved in ethyl acetate.
An adhesive base solution having a solid content concentration of 33.2% by weight was obtained. While stirring 100 parts by weight of crosslinked polyacrylate (“Sun Fresh” manufactured by Sanyo Kasei Co., Ltd.) with a dissolver,
It was added to 100 parts by weight of a 5 wt% HCl aqueous solution and freeze-dried to obtain a cross-linked polyacrylic acid salt impregnated with HCl.

To the above adhesive base solution, indomethacin, H
Cross-linked polyacrylic acid salt impregnated with Cl was added so as to have the composition shown in Table 2, and uniformly mixed by stirring with a dissolver to prepare an ethyl acetate dispersion solution having a solid content concentration of 30% by weight. Using this dispersion solution, a patch was prepared in the same manner as in Example 1.

(Comparative Examples 9 and 10) Patches were prepared in the same manner as in Example 5 except that the pressure-sensitive adhesives were formed using the predetermined amounts of the components shown in Table 2.

(Example 6) Styrene-isoprene-styrene copolymer ("Califlex TR1" manufactured by Shell Chemical Co., Ltd.
107P "), 100 parts by weight, alicyclic saturated hydrocarbon resin (Arakawa Chemical Co., Ltd." Alcon P85 ") 95 parts by weight, and isopropyl myristate 30 parts by weight under nitrogen substitution.
The mixture was uniformly stirred and mixed at 0 ° C. to obtain an adhesive base solution having a solid content concentration of 84% by weight. Further, 100 parts by weight of a crosslinked polyacrylate (“Sun Fresh” manufactured by Sanyo Kasei Co., Ltd.) was added to 100 parts by weight of a 5% by weight HNO ₃ aqueous solution while stirring with a dissolver, and lyophilized to obtain HNO ₃ -impregnated crosslinking. A polyacrylic acid salt was obtained.

The above adhesive base solution was added with nitrogen substitution at 110 ° C.
Then, indomethacin and HNO ₃ impregnated crosslinked polyacrylic acid salt were added so as to have the composition shown in Table 2, and uniformly mixed by stirring with a dissolver to prepare an adhesive solution. Using this adhesive solution, a patch was prepared in the same manner as in Example 1.

(Comparative Examples 11 and 12) Patches were prepared in the same manner as in Example 6 except that the pressure-sensitive adhesives were formed using the prescribed amounts of the components shown in Table 2.

[0062]

[Table 1]

[0063]

[Table 2]

A drug release test was conducted on the patches obtained in the above Examples and Comparative Examples, and the results are shown in Table 3. (1) Drug release test The drug release test was carried out in accordance with the nude mouse skin permeation test. Fran
Fix the skin of the back of the nude mouse on the diffusion cell of z,
A patch of 3.14 cm ² (circle having a diameter of 1 cm) was applied to the skin surface side. The amount of drug (mg / cm ² ) transferred to the receptor solution on the back surface of the skin after 24 hours was measured by high performance liquid chromatography (HPLC). The diffusion cell was kept at a constant temperature of 37 ° C, and the receptor liquid was 20% by weight.
A polyethylene glycol aqueous solution was used.

(2) Adhesive patch impregnation test A patch sample cut into 5 cm × 5 cm was immersed in 500 ml of ion-exchanged water at room temperature for 24 hours, then taken out and the water on the surface of the sample was lightly removed with a filter paper to give an adhesive. By visually observing changes in the layer surface, (b) presence or absence of swelling of the crosslinked polyacrylic acid salt (b) presence or absence of cracks on the surface of the adhesive layer (c) presence or absence of protrusion of the swollen crosslinked polyacrylic acid salt surface did.

[0066]

[Table 3]

[0067]

The composition of the patch of the present invention is as described above, and various drugs such as isosorbide nitrate and indomethacin can be effectively percutaneously or transmucosally absorbed. Furthermore, when the patch of the present invention is administered to the skin and mucous membranes, it absorbs water or sweat evaporated from the skin or mucous membranes and effectively releases the drug.

Claims (1)

[Claims] 1. A patch having a pressure-sensitive adhesive layer provided on one surface of a support, wherein the pressure-sensitive adhesive layer comprises a crosslinked polyacrylic acid salt impregnated with an electrolyte or a strong acid, a drug and a pressure-sensitive adhesive base,
The patch is characterized in that the crosslinked polyacrylate absorbs water and swells, but does not swell with a drug.